Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

scientific article published on 07 November 2019

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41409-019-0731-X
P932PMC publication ID7051903
P698PubMed publication ID31700138

P50authorRafael de la CamaraQ60628685
F Márquez-MalaverQ83200296
Teresa Caballero-VelazquezQ90262472
Christelle FerràQ90463753
Virginia Escamilla GómezQ91174325
Irene García CadenasQ91174327
Paula MolésQ91174331
P2093author name stringEstefanía Pérez
Jorge Sierra
Guillermo Orti
Valentín García-Gutiérrez
Blanca Molina Angulo
José A Pérez-Simón
David Valcárcel Ferreiras
Marc Poch
Grupo Español de Trasplante Hematopoyético (GETH)
Marta González Vicent
Ingrid M Parra Salinas
Dolores Caballero Barrigón
Ildefonso Espigado Tocino
Lucía López Corral
Ariadna Pérez Martínez
Cristina Calderón Cabrera
Isabel Sánchez Ortega
Jaime Sanz Caballer
Juan Montoro Gómez
Kyra Velázquez-Kennedy
María C Viguria Alegría
María João Mende
María T Zudaire Ripa
Miguel A Díaz Pérez
Nancy Rodríguez Torres
Pedro A González Sierra
Rocío Parody Porras
Rodrigo Martino Bofarull
Silvanna Saavedra Gerosa
P2860cites workRuxolitinib: a steroid sparing agent in chronic graft-versus-host diseaseQ49724160
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.Q50092012
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHDQ58782275
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasmsQ60044478
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
Extracorporeal Photopheresis: Tolerogenic or Immunogenic Cell Death? Beyond Current DogmaQ26798468
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisQ33399977
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Current issues in chronic graft-versus-host diseaseQ33917187
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effectQ34301568
Steroid-Refractory Acute GVHD: Predictors and Outcomes.Q35550596
Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisQ35760517
Rituximab for steroid-refractory chronic graft-versus-host diseaseQ35848933
Acute graft versus host diseaseQ36059671
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow TransplantationQ36113205
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.Q36363380
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group reporQ36554724
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyQ36862931
Interleukin-2 and regulatory T cells in graft-versus-host diseaseQ37055805
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.Q37468247
Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical PracticeQ37778478
Extracorporeal photopheresis in acute and chronic graft-versus-host diseaseQ38208102
Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic reviewQ38701847
Sirolimus for treatment of steroid-refractory acute graft-versus-host diseaseQ43228479
Rapamycin for refractory acute graft-versus-host diseaseQ43246106
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivoQ43451422
Ibrutinib for chronic graft-versus-host disease after failure of prior therapyQ46428638
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.Q48259698
P433issue3
P921main subjectruxolitinibQ7383611
P304page(s)641-648
P577publication date2019-11-07
P1433published inBone Marrow TransplantationQ4941523
P1476titleRuxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
P478volume55

Reverse relations

Q89767651Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adultscites workP2860

Search more.